S&P 500   4,274.38 (-1.45%)
DOW   33,624.02 (-1.13%)
QQQ   354.01 (-1.56%)
AAPL   172.13 (-2.24%)
MSFT   310.73 (-2.14%)
META   298.33 (-0.83%)
GOOGL   128.20 (-2.22%)
AMZN   126.04 (-3.98%)
TSLA   243.72 (-1.32%)
NVDA   421.05 (-0.28%)
NIO   8.44 (+1.08%)
BABA   85.79 (-1.64%)
AMD   95.63 (-1.80%)
T   15.02 (-0.27%)
F   12.42 (-1.27%)
MU   67.87 (-1.04%)
CGC   0.89 (-5.73%)
GE   109.86 (-1.66%)
DIS   79.84 (-1.44%)
AMC   7.95 (-2.33%)
PFE   32.53 (-1.36%)
PYPL   58.77 (-0.15%)
NFLX   377.85 (-1.81%)
S&P 500   4,274.38 (-1.45%)
DOW   33,624.02 (-1.13%)
QQQ   354.01 (-1.56%)
AAPL   172.13 (-2.24%)
MSFT   310.73 (-2.14%)
META   298.33 (-0.83%)
GOOGL   128.20 (-2.22%)
AMZN   126.04 (-3.98%)
TSLA   243.72 (-1.32%)
NVDA   421.05 (-0.28%)
NIO   8.44 (+1.08%)
BABA   85.79 (-1.64%)
AMD   95.63 (-1.80%)
T   15.02 (-0.27%)
F   12.42 (-1.27%)
MU   67.87 (-1.04%)
CGC   0.89 (-5.73%)
GE   109.86 (-1.66%)
DIS   79.84 (-1.44%)
AMC   7.95 (-2.33%)
PFE   32.53 (-1.36%)
PYPL   58.77 (-0.15%)
NFLX   377.85 (-1.81%)
S&P 500   4,274.38 (-1.45%)
DOW   33,624.02 (-1.13%)
QQQ   354.01 (-1.56%)
AAPL   172.13 (-2.24%)
MSFT   310.73 (-2.14%)
META   298.33 (-0.83%)
GOOGL   128.20 (-2.22%)
AMZN   126.04 (-3.98%)
TSLA   243.72 (-1.32%)
NVDA   421.05 (-0.28%)
NIO   8.44 (+1.08%)
BABA   85.79 (-1.64%)
AMD   95.63 (-1.80%)
T   15.02 (-0.27%)
F   12.42 (-1.27%)
MU   67.87 (-1.04%)
CGC   0.89 (-5.73%)
GE   109.86 (-1.66%)
DIS   79.84 (-1.44%)
AMC   7.95 (-2.33%)
PFE   32.53 (-1.36%)
PYPL   58.77 (-0.15%)
NFLX   377.85 (-1.81%)
S&P 500   4,274.38 (-1.45%)
DOW   33,624.02 (-1.13%)
QQQ   354.01 (-1.56%)
AAPL   172.13 (-2.24%)
MSFT   310.73 (-2.14%)
META   298.33 (-0.83%)
GOOGL   128.20 (-2.22%)
AMZN   126.04 (-3.98%)
TSLA   243.72 (-1.32%)
NVDA   421.05 (-0.28%)
NIO   8.44 (+1.08%)
BABA   85.79 (-1.64%)
AMD   95.63 (-1.80%)
T   15.02 (-0.27%)
F   12.42 (-1.27%)
MU   67.87 (-1.04%)
CGC   0.89 (-5.73%)
GE   109.86 (-1.66%)
DIS   79.84 (-1.44%)
AMC   7.95 (-2.33%)
PFE   32.53 (-1.36%)
PYPL   58.77 (-0.15%)
NFLX   377.85 (-1.81%)
NASDAQ:BCYC

Bicycle Therapeutics (BCYC) Earnings Date, Estimates & Call Transcripts

$20.22
+0.07 (+0.35%)
(As of 02:47 PM ET)
Compare
Today's Range
$20.09
▼
$21.12
50-Day Range
$20.09
▼
$25.82
52-Week Range
$18.84
▼
$33.49
Volume
106,746 shs
Average Volume
285,680 shs
Market Capitalization
$607.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.75
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Nov. 2Estimated
Actual EPS
(Aug. 3)
-$1.41 Missed By -$0.31
Consensus EPS
(Aug. 3)
-$1.10
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

BCYC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BCYC Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Bicycle Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20236($1.15)($0.81)($1.04)
Q2 20236($1.20)($0.85)($1.07)
Q3 20236($1.29)($0.88)($1.13)
Q4 20236($1.37)($0.95)($1.20)
FY 202324($5.01)($3.49)($4.44)

BCYC Earnings Date and Information

Bicycle Therapeutics last issued its quarterly earnings results on August 3rd, 2023. The reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.10) by $0.31. The business had revenue of $11.40 million for the quarter, compared to the consensus estimate of $13.77 million. Bicycle Therapeutics has generated ($4.68) earnings per share over the last year (($4.68) diluted earnings per share). Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($5.25) to ($5.95) per share. Bicycle Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 2nd, 2023 based off prior year's report dates.

Bicycle Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/2/2023
Estimated)		------- 
8/3/2023Q2 2023($1.10)($1.41)($0.31)($1.41)$13.77 million$11.40 million
5/4/2023Q1 2023($1.06)($1.30)($0.24)($1.30)$4.34 million$4.90 million
2/28/2023Q4 2022($1.06)($1.01)+$0.05($1.01)$3.63 million$3.19 million
11/3/2022Q3 2022($0.98)($0.96)+$0.02($0.96)$4.93 million$3.04 million
8/4/2022Q2 2022($0.82)($0.90)($0.08)($0.90)$3.70 million$4.38 million
5/5/2022Q1 2022($0.70)($0.93)($0.23)($0.93)$3.46 million$3.86 million
3/1/2022Q4 2021($0.60)($0.63)($0.03)($0.63)$6.31 million$3.77 million
11/3/2021Q3 2021($0.61)($0.59)+$0.02($0.59)$5.29 million$4.33 million
8/5/2021Q2 2021($0.71)($0.74)($0.03)($0.74)$2.51 million$1.79 million
5/6/2021Q1 2021($0.68)($0.73)($0.05)($0.73)$1.95 million$1.81 million  
3/10/2021Q4 2020($0.47)($0.83)($0.36)($0.83)$3.24 million$3.85 million
11/5/2020Q3 2020($0.52)($0.52)-($0.52)$1.05 million$3.84 million  












Bicycle Therapeutics Earnings - Frequently Asked Questions

When is Bicycle Therapeutics's earnings date?

Bicycle Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 2nd, 2023 based off last year's report dates. Learn more on BCYC's earnings history.

Did Bicycle Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Bicycle Therapeutics (NASDAQ:BCYC) missed the analysts' consensus estimate of ($1.10) by $0.31 with a reported earnings per share (EPS) of ($1.41). Learn more on analysts' earnings estimate vs. BCYC's actual earnings.

How much revenue does Bicycle Therapeutics generate each year?

Bicycle Therapeutics (NASDAQ:BCYC) has a recorded annual revenue of $14.46 million.

How much profit does Bicycle Therapeutics generate each year?

Bicycle Therapeutics (NASDAQ:BCYC) has a recorded net income of -$112.72 million. BCYC has generated -$4.68 earnings per share over the last four quarters.

What is Bicycle Therapeutics's EPS forecast for next year?

Bicycle Therapeutics's earnings are expected to decrease from ($5.25) per share to ($5.95) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:BCYC) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -